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Patients with hematological malignancies can be suc-
cessfully treated with allogeneic stem cell transplanta-
tion (alloSCT). In HLA-matched alloSCT, donor T cells
can mediate desired anti-tumor immunity as well as
undesired side effects by recognizing minor histocom-
patibility antigens (MiHA) on patient cells. MiHA are
polymorphic peptides with amino acid changes that are
created by genetic variants and recognized by specific
T cells. MiHA with hematopoiesis restricted expression
are relevant targets for immunotherapy to augment
anti-tumor immunity after alloSCT without side effects.
For high-throughput discovery of MiHA, we previously
developed whole genome association scanning (WGAs)
in which T cell recognition of a panel of EBV-B cell lines
is investigated for association with single nucleotide poly-
morphisms (SNPs) to identify the genomic region that
encodes the antigen. Although WGAs is an efficient
strategy for MiHA discovery, strong association with
SNPs in introns or other regions outside coding exons
can be found for approximately one third of the T cell
clones, whereas no SNP disparity in the primary tran-
script is present between patient and donor, suggesting
that the antigen may be encoded by an alternative tran-
script. To identify MiHA encoded by alternative tran-
scripts, we developed an integrated approach in which
WGAs is combined with whole transcriptome data from
the GEUVADIS project.
By performing WGAs, we identified associating SNPs
for two HLA-B*15:01-restricted MiHA that were tar-
geted by donor CD8 T cells in a patient with strong
anti-tumor immunity after HLA-matched alloSCT. One
antigen (LB-GLE1-1V) was encoded by an associating
SNP in exon 6 of the GLE1 gene. For the other antigen,
an associating SNP in intron 3 of the ITGB2 gene was
found, but no SNP disparity was present in the normal
ITGB2 transcript between patient and donor. Therefore,
we investigated whether the antigen may be encoded by
an alternative transcript. Using RNA-sequence data, we
identified an alternative ITGB2 transcript in which part
of intron 3 was retained. Q-PCR analysis showed that
expression of this transcript was restricted to hemato-
poietic cells from SNP-positive individuals. In silico
translation of the transcript revealed a peptide with
strong predicted binding to HLA-B*15:01 (LB-ITGB2-1),
which was recognized by specific T cells. T cells for LB-
ITGB2-1 also recognized and lysed leukemic cells of dif-
ferent origins, while no reactivity against patient fibro-
blasts could be detected.
In summary, RNA-sequence analysis enabled discovery
of LB-ITGB2-1 as immune epitope encoded by an alterna-
tive gene transcript. Our data support the therapeutic rele-
vance of LB-ITGB2-1 as target for T cell therapy to
stimulate anti-tumor immunity after alloSCT.
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